Aptevo Therapeutics
APVO
9 hedge funds and large institutions have $599K invested in Aptevo Therapeutics in 2024 Q2 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
4,733% more capital invested
Capital invested by funds: $12.4K → $599K (+$587K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$836K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$567K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$567K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$134K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$29.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Truvestments Capital
Sarasota,
Florida
|
-$9 |
APVO Hedge Fund Activity: Q2 2024 in Review
9 of the 6,926 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q2 2024, worth a combined $599K — up 4,733% from $12.4K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new APVO positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $836K. The largest seller was Truvestments Capital, cutting an estimated $9.
- 9 institutional investors held Aptevo Therapeutics (APVO) as of Q2 2024, up from 0 in Q1 2024.
- Funds reported $599K of Aptevo Therapeutics stock for Q2 2024, up 4,733% quarter-over-quarter.
- 9 funds opened new Aptevo Therapeutics positions in Q2 2024 and 0 closed out, a net change of +9 holders.
- The largest Aptevo Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $836K added.
- The largest Aptevo Therapeutics seller in Q2 2024 was Truvestments Capital, an estimated $9 sold.
Based on aggregated 13F filings for Q2 2024.